Ann: Letter to Shareholders - GM, page-5

First 5 Last

Share
Profile

Follow
pakkham

13,179 Posts.

685

05/04/24

11:53

Post #: 73204690
Share

Originally posted by PhantomGWW: ↑

Hi Prora-------------------------- as an ex-shareholder I would suggest you gather some facts and present it to ASIC............\

It must be facts. Unfortunately we 'plebs' sit on our brains- complain and hope someone else does the work/reporting. Nothing happens till one does something - same as politicians - they know we 'plebs' forget after awhile -------------- true.
Also when presenting - if one does-- make sure (again facts you can back up) you put :
cc John Laws -A Current Affair - ABC- Sky News- Ben Fordham - etc and as many Pollies on the opposite side as you can. I know this has an effect- was once a clerk to a MD of one of the big banks - many years ago --- he told me ' xxxxx if you want some thing to be acted on - let others know what the 'gripe is' - especially when it is apart of their area------------------- works wonders - Oh in some cases you no need to send the cc. but they recipient does not know that.

I am also piss-- of with some up/down rampers and believe I have enough facts to present to ASIC - only problem I have heard ASIC is a tiger without teeth
That comment is an opinion from comments with HC ????????

Good luck guys ................ Any 'thoughts' without effort and action are as 'useless as an ashtray on a motorbike'/ 'screen window on a sub'

PS make sure the cc's are on each one you send to ---------- they then know - many know - not just one !

PSS this is all my opinion -- do some research.

All keep safe --------------------

Expand

well
Miracle happen??
ride the wave .. jump the tide
i sold on criterias

RGS Price at posting: 1.4¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

First 5 Last

Add CMB (ASX) to my watchlist

(20min delay)
Last 39.0¢		Change -0.005(1.27%)		Mkt cap ! $4.653M

Open	High	Low	Value	Volume
39.0¢	39.0¢	39.0¢	$0	1

Buyers (Bids)

No.	Vol.	Price($)
1	2780	36.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	1	1

View Market Depth

No.	Vol.	Price($)
1	2780	0.360
1	2000	0.310
2	2500	0.300
1	2632	0.190
0	0	0.000

Price($)	Vol.	No.
0.385	1	1
0.390	999	1
0.395	12042	1
0.400	157	1
0.410	2000	1

Last trade - 12.00pm 07/10/2024 (20 minute delay)

CMB (ASX) Chart

Ann: Letter to Shareholders - GM, page-5

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Letter to Shareholders - GM, page-5

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News